Quantcast
Channel: Articles tagged with Obesity from Medical Marketing and Media
Browsing all 75 articles
Browse latest View live

Company news: Burson-Marsteller, Corcept and Orexigen

PR firm Burson-Marsteller launched a new healthcare subsidiary, Orexigen's net loss widened in Q2, and Corcept closed out its first full quarter with orphan treatment Korlym.

View Article



Company news: Vivus and Genentech

Genentech braced for a Boniva patent cliff, only to come up short, and Vivus' branded obesity drug may face immediate generic competition.

View Article

Study cites surgery's role in preventing type-2 diabetes

A study says bariatric surgery can keep patients from becoming diabetic. A bariatric surgeon told MM&M that, while the result isn't a surprise, he doesn't expect the findings to cause the number of...

View Article

FDA, EMA take yo-yo approach on diet pills

Moves by regulators indicate that the yo-yo effect is not just a patient phenomenon, but one that afflicts drugmakers as well.

View Article

Allergan may shed obesity business, GSK a chairman

The two companies reported third-quarter earnings along with corporate shake-up news.

View Article


Weight-loss category enters 2013 light on results

The category that saw its first FDA-approved drug in 13 years is still waiting to take off.

View Article

Company news: Time, Takeda, Amylin, PwC

Time Inc. targeted media brand focuses on pharma; Takeda and Amylin call it quits on obesity partnership; PricewaterhouseCoopers builds regulatory intelligence unit

View Article

Vivus launches Qsymia weight-loss app

The drug maker is promoting the no-fee, all-access app to healthcare professionals as part of its Qsymia pitch.

View Article


Business briefs: HRT, HPV, Novo Nordisk

Researchers find weaknesses in HRT-breast cancer studies, Novo announces GLP-1 weight loss results

View Article


Hyperbolic OTC obesity drug ads backfire

When it comes to OTC weight-loss products, deceptive advertising produces diminishing returns, a study has found.

View Article

Analysts on Qsymia: show me the payers

Analysts write expanded Qsymia distribution will do little to boost sales if payers are not on board.

View Article

Business briefs: Arena, Takeda, Teva, Cubist

Arena gets closer to the market place, Takeda scoops up privately held Inviragen, Plan B court decision is coming and Cubist antibotic lands breakthrough therapy status.

View Article

Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity

HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.

View Article


Orexigen, Vivus remain in weight-loss limbo

Quarterly reports show that that the weight loss category remains a cool one, but studies indicate that even the best marketing plan will have to overcome payer and pricing issues.

View Article

Business briefs: AbbVie, AstraZeneca, Valeant, Merck, Novo Nordisk

AbbVie's Niaspan pricing gets a hard look; AstraZeneca buys up heart drug and company; Valeant expands eye care portfolio with B&L; Merck halts Parkinson's study; Novo explores liraglutide weight...

View Article


Weight-loss category expands by one

Eisai brings Belivq to 20,000 US pharmacies, along with 200 sales reps and a physician marketing push.

View Article

Business briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN

Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site

View Article


Business briefs: Alexion, AMA, Eli Lilly

Alexion plans on moving into new HQ in 2015, AMA declares obesity is a disease, FDA looks into Zyprexa patient deaths

View Article

Novo, Deen agree to suspend their relationship

Novo Nordisk stresses that the company has not parted ways with Paula Deen, even as her other endorsement and business deals shrivel up.

View Article

Obesity marketing to stay same, despite new AMA designation

Drug makers say the AMA's labeling of obesity as a disease will prompt patient-physician conversations, but they have no plans to overhaul brands' messaging.

View Article
Browsing all 75 articles
Browse latest View live




Latest Images